Millipore (MIL) 10-Q 2003 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2003 or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES ACT OF 1934

For the transition period from                to                

Commission File Number 001-09781 (0-1052)

MILLIPORE CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	04-2170233
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
290 Concord Road, Billerica, MA	01821
(Address of principal executive offices)	(Zip Code)

(978) 715-4321

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x  No  ¨

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2).  Yes  x  No  ¨

As of October 24, 2003, there were 48,807,236 shares of the registrant’s Common Stock outstanding.

MILLIPORE CORPORATION

INDEX TO FORM 10-Q

PART I.	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets at September 30, 2003 and December 31, 2002	3
	Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2003 and 2002	4
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2003 and 2002	5
	Notes to Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosure about Market Risk	23
Item 4.	Controls and Procedures	23
PART II.	OTHER INFORMATION
Item 6.	Exhibits and Reports on Form 8-K	23
Signatures		24

2

MILLIPORE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2003			December 31, 2002
	(In thousands)
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	153,104		$	101,242
Accounts receivable, net		177,914			160,462
Inventories		132,963			111,332
Deferred income taxes		11,694			11,694
Other current assets		7,212			5,481
Total current assets		482,887			390,211
Property, plant and equipment, net		293,247			262,604
Deferred income taxes		87,824			87,824
Intangible assets, net		25,933			28,064
Goodwill		9,433			9,646
Other assets		6,779			7,881
Total assets	$	906,103		$	786,230
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Notes payable	$	—		$	1,500
Accounts payable		62,409			57,596
Accrued expenses		66,200			58,431
Accrued retirement plan contributions		7,933			8,438
Accrued income taxes payable		14,233			8,464
Total current liabilities		150,775			134,429
Long-term debt		330,000			334,000
Other liabilities		33,257			30,297
Total liabilities		514,032			498,726
Commitments and contingencies		—			—
Shareholders’ equity:
Common stock		56,988			56,988
Additional paid-in capital		91,338			91,338
Retained earnings		500,231			432,139
Unearned compensation		(836	)		(1,454	)
Accumulated other comprehensive loss		(15,563	)		(40,700	)
		632,158			538,311
Less: Treasury stock at cost, 8,210 and 8,576 shares, respectively		(240,087	)		(250,807	)
Total shareholders’ equity		392,071			287,504
Total liabilities and shareholders’ equity	$	906,103		$	786,230

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

MILLIPORE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

	Three Months Ended September 30,						Nine Months Ended September 30,
	2003			2002			2003			2002
	(In thousands, except per share data)
	(Unaudited)
Net sales	$	200,053		$	175,616		$	583,872		$	518,372
Cost of sales		91,563			76,795			262,423			220,845
Gross profit		108,490			98,821			321,449			297,527
Selling, general and administrative expenses		60,030			54,226			181,869			163,070
Research and development expenses		14,030			12,940			41,908			38,858
Restructuring and other		(796	)		525			(1,400	)		1,025
Operating income		35,226			31,130			99,072			94,574
Loss on investments		—			(2,344	)		—			(2,344	)
Interest income		441			354			1,205			876
Interest expense		(3,980	)		(4,942	)		(12,317	)		(15,035	)
Income before income taxes		31,687			24,198			87,960			78,071
Provision for income taxes		7,130			5,324			19,791			17,176
Income from continuing operations		24,557			18,874			68,169			60,895
Income on disposal of discontinued operations, net of taxes		—			—			—			2,900
Net income	$	24,557		$	18,874		$	68,169		$	63,795
Basic income per share:
Continuing operations	$	0.50		$	0.39		$	1.41		$	1.27
Discontinued operations		—			—			—			0.06
Net income	$	0.50		$	0.39		$	1.41		$	1.33
Diluted income per share:
Continuing operations	$	0.50		$	0.39		$	1.39		$	1.26
Discontinued operations		—			—			—			0.06
Net income	$	0.50		$	0.39		$	1.39		$	1.32
Weighted average shares outstanding:
Basic		48,630			48,266			48,499			48,112
Diluted		49,356			48,405			48,899			48,441

The accompanying notes are an integral part of the condensed consolidated financial statements.

4

MILLIPORE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine months ended September 30,
	2003			2002
	(In thousands)
	(Unaudited)
Cash flows from operating activities:
Net income	$	68,169		$	63,795
Less: Income on disposal of discontinued operations, net of taxes		—			2,900
Income from continuing operations		68,169			60,895
Adjustments to reconcile income from continuing operations to net cash provided by operating activities:
Depreciation and amortization		29,740			25,190
Gain on sale of property, plant and equipment		(796	)		—
Change in operating assets and liabilities:
(Increase) decrease in accounts receivable		(8,701	)		9,519
Increase in inventories		(14,759	)		(17,554	)
Increase in other current assets		(1,487	)		(1,629	)
Decrease in other assets		1,436			3,016
Increase (decrease) in accounts payable and accrued expenses		7,164			(8,447	)
Decrease in accrued retirement plan contributions		(763	)		(1,353	)
Increase (decrease) in accrued income taxes		5,737			(2,385	)
Increase in other		2,481			1,815
Net cash provided by operating activities		88,221			69,067
Cash flows from investing activities:
Additions to property, plant and equipment		(49,326	)		(48,121	)
Proceeds from sale of property, plant and equipment		1,250			—
Acquisition		—			(11,676	)
Additions to investments and intangible assets		—			(2,609	)
Net cash used in investing activities		(48,076	)		(62,406	)
Cash flows from financing activities:
Proceeds from issuance of treasury stock under stock plans		10,611			13,749
Net (repayments of) proceeds from revolver borrowings		(5,500	)		16,142
Dividends paid		—			(5,266	)
Net cash provided by financing activities		5,111			24,625
Effect of foreign exchange rates on cash and cash equivalents		6,606			666
Net cash provided by continuing operations		51,862			31,952
Net cash used by discontinued operations		—			(3,452	)
Net increase in cash and cash equivalents		51,862			28,500
Cash and cash equivalents on January 1		101,242			62,450
Cash and cash equivalents on September 30	$	153,104		$	90,950

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

MILLIPORE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except per share data)

1.    General

Millipore Corporation (“Millipore”, “our” or “we”) is a multinational bioscience company that provides technologies, tools and services for the discovery, development and production of therapeutic drugs and for other purposes. Our products serve the worldwide biotechnology and life science research markets as well as other bioscience markets. Our products are based on a variety of enabling technologies, including our membrane filtration and chromatography technologies.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, accordingly, these footnotes condense or omit information and disclosures which substantially duplicate information provided in our latest audited financial statements. These financial statements should be read in conjunction with the financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2002. In the opinion of our management, these financial statements reflect all adjustments necessary for a fair presentation of the results for the interim periods presented. The accompanying unaudited condensed consolidated financial statements are not necessarily indicative of future trends or our operations for the entire year. Reclassifications have been made to prior year financial statements to conform to the 2003 presentation.

2.    Stock-based Compensation

At September 30, 2003, we have a stock-based employee compensation plan and a non-employee director stock option plan from which we currently grant stock options. We apply the recognition and measurement provisions of Accounting Principles Board Opinion No. 25 (“APB 25”), “Accounting for Stock Issued to Employees,” and related interpretations in accounting for those plans. No stock-based compensation expense is reflected in net income as all options granted under the plans had an exercise price equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share if we had applied the fair value recognition provisions of Statement of Financial Accounting Standards (“SFAS”) No. 123, “Accounting for Stock-based Compensation,” to stock-based employee compensation for the three and nine months ended September 30, 2003 and 2002.

	Three months ended September 30,				Nine months ended September 30,
	2003		2002		2003		2002
Net income, as reported	$	24,557	$	18,874	$	68,169	$	63,795
Add: Stock-based employee compensation expense included in reported net income, net of related tax effects		160		386		480		739
Deduct: Stock-based employee compensation expense determined under fair value based method, net of related tax effects, pro forma		5,067		3,995		15,200		11,625
Pro forma net income	$	19,650	$	15,265	$	53,449	$	52,909
Earnings per share:
Basic, as reported	$	0.50	$	0.39	$	1.41	$	1.33
Basic, pro forma	$	0.40	$	0.32	$	1.10	$	1.10
Diluted, as reported	$	0.50	$	0.39	$	1.39	$	1.32
Diluted, pro forma	$	0.40	$	0.32	$	1.09	$	1.09

6

MILLIPORE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(In thousands, except per share data)

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes model. The assumptions used in the Black-Scholes calculation for the three and nine months ended September 30, 2003 and 2002 included an expected life of five years, a dividend rate of zero, expected volatility of 40% and a weighted average risk-free interest rate of 4.2%.

3.    Inventories

Inventories at September 30, 2003 and December 31, 2002, stated at the lower of first-in, first-out (“FIFO”) cost or market, consisted of the following:

	September 30, 2003		December 31, 2002
Raw materials	$	52,379	$	44,156
Work in process		21,566		16,006
Finished goods		59,018		51,170
	$	132,963	$	111,332

At September 30, 2003, approximately $2,500 of inventory is related to purchases of key raw materials which are not expected to be used within the next 12 months. At December 31, 2002, approximately $1,600 of inventory was related to purchases of key raw materials which were not expected to be used prior to December 31, 2003.

4.    Property, Plant and Equipment

Accumulated depreciation on property, plant and equipment was $210,917 at September 30, 2003 and $183,006 at December 31, 2002.

During the nine months ended September 30, 2003, we invested $445, for a cumulative total of $7,908 invested to date, related to a planned $30,000 project to expand manufacturing capacity adjacent to our existing manufacturing facility in Ireland. We do not expect to complete construction of this facility prior to 2006. This facility is currently a multipurpose building shell that is expected to increase manufacturing capacity for a core consumable product line. If necessary, this facility could be used for the manufacturing of alternative products.

5.    Intangible Assets, net

Intangible assets consisted of the following at September 30, 2003 and December 31, 2002:

September 30, 2003	Gross Intangible Assets		Accumulated Amortization			Net Intangible Assets		Estimated Useful Life
Patented and unpatented technology	$	22,399	$	(11,955	)	$	10,444	4–20 years
Trade names		18,995		(6,038	)		12,957	8–20 years
Licenses and other		5,179		(2,647	)		2,532	5–10 years
Total	$	46,573	$	(20,640	)	$	25,933
December 31, 2002
Patented and unpatented technology	$	22,399	$	(10,630	)	$	11,769	4–20 years
Trade names		18,995		(5,136	)		13,859	8–20 years
Licenses and other		6,302		(3,866	)		2,436	5–10 years
Total	$	47,696	$	(19,632	)	$	28,064

7

MILLIPORE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(In thousands, except per share data)

Amortization expense for the nine months ended September 30, 2003 and 2002 was $2,550 and $2,800 respectively.

The estimated aggregate amortization expense for intangible assets owned as of September 30, 2003 for each of the five succeeding years is as follows:

Remainder of 2003	$	850
2004		3,310
2005		3,100
2006		2,950
2007		1,970
Thereafter		13,753
	$	25,933

6.    Restructuring Program and Other

During the quarter ended September 30, 2003, we received proceeds of $1,250 and realized a gain of $796 in connection with a sale of real estate. During the nine months ended September 30, 2003, we completed the restructuring program that had been initiated during 2001 and also recovered approximately $250 in assets that we had originally written-off and deemed uncollectible. Upon completion of this restructuring program during the quarter ended June 30, 2003, we reversed $604 of the original estimated reserve, which included the $250 that was recovered and $354 of previously estimated lease and severance payments, as these amounts were no longer required. We eliminated 215 positions which resulted in approximately 190 employees leaving Millipore.

During the quarter ended September 30, 2002, we recorded an additional charge of $525 resulting in a charge of $1,025 during the nine months ended September 30, 2002 related to litigation that was settled during the quarter ended December 31, 2002.

7.    Discontinued Operations

On October 3, 2000, we announced our plans, subject to certain conditions, to separate into two distinct companies by making our Microelectronics business segment an independent, publicly traded company. In accordance with these plans, the Microelectronics business segment was separated into a wholly owned Millipore subsidiary named Mykrolis Corporation (“Mykrolis”) on March 31, 2001. On August 9, 2001, Mykrolis completed an initial public offering (the “Mykrolis IPO”) of 7,000 Mykrolis common shares at a price of $15.00 per share. Prior to the Mykrolis IPO, our ownership in Mykrolis’ outstanding common shares was 100%, and at December 31, 2001 our ownership in Mykrolis’ outstanding common shares was approximately 82%. On February 27, 2002 (the “Distribution Date”), we distributed our remaining ownership interest in Mykrolis common stock as a dividend to our shareholders of record as of February 13, 2002. During the first quarter of 2002, the amount of loss from discontinued operations that we had estimated during the year ended December 31, 2001 was reduced by $2,900 to reflect the actual net loss of Mykrolis through the Distribution Date.

8.    Basic and Diluted Earnings per Share

In addition to the 48,630 and 48,499 weighted average shares outstanding for the three and nine months ended September 30, 2003, respectively, there were 726 and 400 stock options and shares of restricted stock that had a dilutive effect during the three and nine months ended September 30, 2003, respectively. Including the

8

MILLIPORE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(In thousands, except per share data)

dilutive effect of the stock options and shares of restricted stock, there were 49,356 and 48,899 weighted average shares outstanding on a diluted basis for the three and nine months ended September 30, 2003, respectively.

In addition to the 48,266 and 48,112 weighted average shares outstanding for the three and nine months ended September 30, 2002, respectively, there were 139 and 329 stock options and shares of restricted stock that had a dilutive effect during the three and nine months ended September 30, 2002, respectively. Including the dilutive effect of the stock options and shares of restricted stock, there were 48,405 and 48,441 weighted average shares outstanding on a diluted basis for the three and nine months ended September 30, 2002, respectively.

For the three months ended September 30, 2003 and September 30, 2002, 1,817 and 3,266, respectively, of outstanding stock options were excluded from the calculation of diluted earnings per share because their inclusion would have been antidilutive. For the nine months ended September 30, 2003 and September 30, 2002, 2,889 and 3,056, respectively, of outstanding stock options were excluded from the calculation of diluted earnings per share because their inclusion would have been antidilutive. Antidilutive options could be dilutive in the future.

9.    Comprehensive Income

The following table presents the components of comprehensive income, net of taxes:

	Three Months Ended September 30,					Nine months ended September 30,
	2003		2002			2003		2002
Net unrealized gain (loss) on securities available for sale	$	10	$	45		$	15	$	(48	)
Foreign currency translation adjustments		4,235		(3,079	)		25,122		17,289
Other comprehensive income (loss)		4,245		(3,034	)		25,137		17,241
Net income		24,557		18,874			68,169		63,795
Total comprehensive income	$	28,802	$	15,840		$	93,306	$	81,036

10.    Business Segment Information

SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information,” establishes standards for reporting information about operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports. It also establishes standards for related disclosures about products and services, geographic areas and major customers. We evaluated our business activities that are regularly reviewed by our chief decision-makers for which separate discrete financial information is available. As a result of this evaluation, we determined that we have three operating segments: BioPharmaceutical, Laboratory Water and Life Sciences, which are aggregated into one reporting segment.

BioPharmaceutical develops, manufactures and sells consumable products and hardware and provides related services used principally in development and manufacturing of therapeutic products. Laboratory Water and Life Sciences manufacture and sell instrumentation, consumable products and services used in drug discovery and other laboratory applications. For all three of these operating segments, economic characteristics, production processes, products and services, types and classes of customers, methods of distribution and regulatory environments are similar. Further, our chief decision-makers evaluate our performance and make resource allocation decisions based on total consolidated company results. Accordingly, the three segments have been aggregated into one reporting segment for financial statement purposes.

9

MILLIPORE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(In thousands, except per share data)

11.    Commitments and Contingencies

We are subject to a number of claims and legal proceedings which, in our opinion, are incidental to our normal business operations. In our opinion, although final settlement of these suits and claims may impact our consolidated financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on our consolidated financial position, results of operations and cash flows.

In November 2002, the FASB issued FASB Interpretation No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, an interpretation of FASB Statement Nos. 5, 57, and 107 and Rescission of FASB Interpretation No. 34.” FIN 45 clarifies the requirements of FASB Statement No. 5, “Accounting for Contingencies,” relating to the guarantor’s accounting for, and disclosure of, the issuance of certain types of guarantees. FIN 45 requires that upon issuance of a guarantee, the guarantor must recognize a liability for the fair value of the obligation it assumes under that guarantee. FIN 45 also requires additional disclosures by a guarantor in its interim and annual financial statements about the obligations associated with guarantees issued. The recognition and measurement provisions are effective on a prospective basis to guarantees issued or modified after December 31, 2002. The adoption of FIN 45 did not have an impact on our condensed consolidated financial statements.

As permitted under Massachusetts law and required by our corporate by-laws, we indemnify our officers and directors for certain events or occurrences while the director or officer is or was serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have a Directors and Officers liability insurance policy that enables us to recover a portion of any future amounts paid. As these indemnification obligations were in effect prior to December 31, 2002 these obligations were grandfathered under the provisions of FIN 45. As there were no known or pending claims, we have not accrued a liability for these agreements as of September 30, 2003.

In the ordinary course of business, we warrant to our customers that our products will conform to our published specifications. Generally, the applicable product warranty period is one year from the date of delivery of the product to the customer or of site acceptance, if required. Additionally, we typically provide limited warranties with respect to our services. From time to time, we also make other warranties to our customers, including warranties that our products are manufactured in accordance with applicable laws and not in violation of third party rights. We provide for estimated warranty costs at the time of the product sale. We believe our warranty reserve as of September 30, 2003 appropriately reflects the estimated cost of our warranty obligations.

In the ordinary course of business, we agree from time to time to indemnify certain customers against certain third party claims for property damage, bodily injury, personal injury or intellectual property infringement arising from the operation or use of our products. Also, from time to time in agreements with our suppliers, licensors and other business partners, we agree to indemnify these partners against certain liabilities arising out of the sale or use of our products. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have general and umbrella insurance policies that enable us to recover a portion of any amounts paid. Based on our experience with such indemnification claims, we believe the estimated fair value of these obligations is minimal. Accordingly, we have no liabilities recorded for these agreements as of September 30, 2003.

As part of our past acquisitions and divestitures of businesses or assets, we have provided a variety of warranties and indemnifications to the sellers and purchasers that are typical for such transactions. Typically certain of the warranties and the indemnifications expire after a defined period of time following the transaction, but certain warranties and indemnifications may survive indefinitely. In the case of our spin-off of Mykrolis, we

10

MILLIPORE CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(In thousands, except per share data)

agreed to indemnify Mykrolis against any liability associated with Millipore’s bioscience businesses, whether arising prior to or following the Distribution Date. We also retain contingent liability under certain lease agreements that were assigned to Mykrolis as part of the spin-off. The warranty and indemnification obligations noted above were grandfathered under the provisions of FIN 45 as they were in effect prior to December 31, 2002. Accordingly, we have no liabilities recorded for these obligations as of September 30, 2003. As of September 30, 2003, no material claims under these warranties or indemnifications have been asserted, and we do not know of any such claims being contemplated.

12.    Other New Accounting Pronouncements

In May 2003, FASB issued SFAS No. 150, “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity”. SFAS No. 150 establishes standards on the classification and measurement of financial instruments with characteristics of both liabilities and equity. SFAS No. 150 is effective for financial instruments entered into or modified after May 31, 2003. The adoption of SFAS No. 150 did not have an impact on our consolidated financial statements.

In April 2003, the FASB issued SFAS No. 149,“Amendment of Statement 133 on Derivative Instruments and Hedging Activities”. This statement amends SFAS No. 133 to provide clarification on the financial accounting and reporting of derivative instruments and hedging activities and requires contracts with similar characteristics to be accounted for on a comparable basis. The adoption of SFAS No. 149 did not have an impact on our consolidated financial statements.

In November 2002, the EITF reached a consensus on Issue No. 00-21, “Accounting for Revenue Arrangements with Multiple Deliverables.” This statement provides guidance on how to account for revenue arrangements that involve the delivery or performance of multiple products, services and/or rights to use assets. The provisions of this EITF are effective for revenue arrangements entered into or modified in fiscal periods beginning after June 15, 2003. The adoption of EITF No. 00-21 did not have an impact on our consolidated financial statements.

11

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The Company

Millipore Corporation (“Millipore”, “our” or “we”) is a multinational bioscience company that provides technologies, tools and services for the discovery, development and production of therapeutic drugs and for other purposes. Our products serve the worldwide biotechnology and life science research markets as well as other bioscience markets. The biotechnology market consists of companies that manufacture biotherapeutics. The life science research market consists of research activities in drug discovery, protein applications and genomics within private and publicly funded organizations. The other bioscience market principally includes businesses which develop and manufacture non-biotechnology pharmaceuticals, have clinical and analytical laboratory activities, or conduct processing and quality control of beverages. Our products are based on a variety of enabling technologies, including our membrane filtration and chromatography technologies.

Basis of Presentation and Use of Non-GAAP Financial Measures

The following discussion of the Results of Operations includes reference to “local currencies” which are non-GAAP financial measures. Local currency results represent the foreign currency balances translated to U.S. dollars, in all periods presented, at Millipore’s predetermined budgeted exchange rates for 2003, thus excluding the impact of fluctuations in the actual foreign currency rates. Our management uses this presentation for internal evaluation of our financial performance because we believe that the local currency results provide a clearer presentation of underlying business trends. The U.S. dollar results represent the foreign currency balances translated at actual exchange rates. Unless otherwise indicated, all items refer to continuing operations only and amounts are in thousands, except per share data.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Our most critical accounting policies had a significant impact on the preparation of these condensed consolidated financial statements. These policies include estimates and significant judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continue to have the same critical accounting policies and estimates as we described in Item 7, on page 11, in our Annual Report on Form 10-K for the year ended December 31, 2002. Those policies and estimates were identified as those relating to revenue recognition, allowance for doubtful accounts, inventory valuation analysis, valuation of long-lived assets, income tax provision, employee retirement plans and our intention to refinance short-term debt on a long-term basis. We continue to evaluate our estimates and judgments on an on-going basis. By their nature, these estimates and judgments are subject to an inherent degree of uncertainty. We base our estimates and judgments on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions.

Results of Operations

Third Quarter of 2003 Compared to the Third Quarter of 2002

Net Sales

The following discussion of net sales summarizes sales growth by the geographies in which our products were sold, the markets in which our products were used and major product types.

12

Net Sales by Geography

Sales growth by geography, measured in U.S. dollars and local currencies, for the three months ended September 30 (“third quarter”), 2003 as compared with the third quarter of 2002 is summarized in the table below.

Sales by geography in U.S. dollars	Net sales				Percentage sales growth
	2003		2002
Americas	$	85,072	$	79,568	7	%
Europe		81,525		65,225	25	%
Asia/Pacific		33,456		30,823	9	%
Consolidated U.S. dollar net sales	$	200,053	$	175,616	14	%

Sales by geography in local currencies	Net sales					Percentage sales growth
	2003		2002
Americas	$	85,109	$	79,775		7	%
Europe		74,173		66,190		12	%
Asia/Pacific		33,376		31,584		6	%
Consolidated in local currencies		192,658		177,549		9	%
Foreign exchange		7,395		(1,933	)
Consolidated U.S. dollar net sales	$	200,053	$	175,616		14	%

	Percentage of net sales in U.S. dollars				Percentage of net sales in local currencies
	2003		2002		2003		2002
Americas	42	%	45	%	44	%	45	%
Europe	41	%	37	%	39	%	37	%
Asia/Pacific	17	%	18	%	17	%	18	%
Total	100	%	100	%	100	%	100	%

Net sales for the third quarter of 2003, measured in U.S. dollars, increased 14% as compared with net sales during the third quarter of 2002. Local currency sales increased 9% in the third quarter of 2003 as compared with the third quarter of 2002. The primary currency impacting the difference between U.S. dollar results and local currency results was the Euro. During the third quarter of 2003 as compared with the third quarter of 2002, the U.S. dollar was weaker against the Euro by almost 13%. A weaker U.S. dollar will positively impact U.S. dollar sales growth.

Local currency sales in the Americas increased 7% in the third quarter of 2003 as compared with the third quarter of 2002. The U.S., which comprises over 90% of the total Americas sales, saw an increase in sales during the third quarter of 2003 due to higher sales of hardware products within the biotechnology market and increased sales of consumable products in our other bioscience market. Local currency sales in Latin America increased 30%, off of a small base, in the third quarter of 2003 as compared with the third quarter of 2002, due to continued increases in sales of consumable products to pharmaceutical customers.

Local currency sales in Europe increased 12% during the third quarter of 2003 as compared with the third quarter of 2002. This increase was primarily due to a $7,250 shipment of chromatography media, a consumable product, in the biotechnology market and to a lesser extent increased sales of consumable products in our other bioscience market. Sales within Europe’s life science research market increased 3%. Europe’s sales growth continues to be impacted by the weak capital markets and weak economic conditions resulting in slower growth in demand for our life science research products.

13

Local currency sales in the Asia/Pacific region increased 6% in the third quarter of 2003 as compared with the third quarter of 2002. A majority of our sales within the Asia/Pacific region are to customers in the other bioscience market and our sales within this market increased 3%. Our sales increased 14% in the biotechnology market within the Asia/Pacific region which is in its embryonic stage.

Net Sales by Market

We sell our products into three markets: biotechnology, life science research and other bioscience. Some of our products are unique to one of the markets and some are sold in multiple markets. A product’s market is determined based on our understanding of the customers’ intended use.

Net sales growth in local currency for the third quarter of 2003 as compared with the third quarter of 2002, by market, is summarized in the table below.

Sales by market in local currencies	Net sales					Percentage sales growth
	2003		2002
Biotechnology	$	68,305	$	58,900		16	%
Life Science Research		26,325		24,972		5	%
Other Bioscience		98,028		93,677		5	%
Total local currency net sales by market		192,658		177,549		9	%
Foreign exchange		7,395		(1,933	)
Total U.S. dollar net sales by market	$	200,053	$	175,616		14	%

	Percentage of net sales in local currency
	2003		2002
Biotechnology	35	%	33	%
Life Science Research	14	%	14	%
Other Bioscience	51	%	53	%
Total	100	%	100	%

Local currency sales grew 16% in the biotechnology market during the third quarter of 2003 as compared with the third quarter of 2002. Approximately 80% of sales within the biotechnology market are consumable products which grew at 13%. The increase in sales of our consumable products within the biotechnology market was primarily due to a $7,250 shipment of chromatography media which will be used to validate and qualify a new manufacturing process in a European facility. The demand for our products is impacted by customers’ therapeutic production volumes, major capacity expansions, timing of drug approvals and their commercial success as well as process yields, deployment of new process developments and utilization of contract manufacturers. Therefore, the product demand from customers in this market may vary significantly on a quarterly basis. Geographically, biotechnology sales grew by approximately 22% in Europe and 11% in the Americas.

Local currency sales grew 5% in the life science research market during the third quarter of 2003 as compared with the third quarter of 2002. Our sales in protein applications and drug discovery continue to gain positive momentum while sales in genomics applications were relatively flat.

14

Local currency sales grew 5% in the other bioscience market during the third quarter of 2003 as compared with the third quarter of 2002. This increase was primarily due to increased sales of consumable products to both pharmaceutical and laboratory customers. Geographically, other bioscience sales grew by approximately 7% in Europe, 4% in the Americas and 3% in Asia/Pacific.

Net Sales by Major Product Type

We divide our product offerings into three categories: consumables, hardware and services. Consumables is the largest category with approximately 79% of net sales during the third quarter of 2003 and the third quarter of 2002. Consumables include products such as laboratory sample preparation and screening devices and kits in various low and high throughput formats, specialty membranes and large process scale cartridges manufactured in various flat or cylindrical formats. Hardware sales represented approximately 18% in each respective period. Hardware products include items such as small benchtop filtration systems and cartridge integrity testers, large stainless steel process scale filtration and chromatography systems and columns costing up to several million dollars as well as a variety of systems for laboratory water purification. Consumables typically have higher profit margins than hardware. The services category represents approximately 3% of net sales in each respective period. Included in this category are field services for the maintenance of laboratory water purification systems and validation services offered to biotechnology and non-biotechnology pharmaceutical customers.

Net sales growth by product type, measured in local currencies for the third quarter of 2003 as compared with the third quarter of 2002, is summarized in the table below.

Sales by product type in local currencies	Net sales					Percentage sales growth
	2003		2002
Consumables	$	151,484	$	139,817		8	%
Hardware		34,609		32,117		8	%
Services		6,565		5,615		17	%
Total local currency net sales by product		192,658		177,549		9	%
Foreign exchange		7,395		(1,933	)
Total U.S. dollar net sales by product	$	200,053	$	175,616		14	%

	Percentage of net sales in local currency
	2003		2002
Consumables	79	%	79	%
Hardware	18	%	18	%
Services	3	%	3	%
Total	100	%	100	%

Local currency sales growth of 8% in consumables during the third quarter of 2003 as compared with the third quarter of 2002 was primarily attributable to a $7,250 sale of chromatography media within the European biotechnology market and due to increased sales in the other bioscience market. Sales of consumables in the other bioscience market increased nearly 12% in Europe and almost 10% in the Americas, while remaining relatively flat in the Asia/Pacific region.

Local currency sales growth of 8% in hardware during the third quarter of 2003 as compared with the third quarter of 2002 was primarily to customers within the biotechnology market. This quarter’s increase is a result of a number of hardware projects that were delayed by our customers in prior quarters, primarily in the Americas, being started during the third quarter of 2003 as well as unusually low sales during the third quarter of 2002. The demand for our hardware is impacted by customers’ major capacity expansions, therefore, demand may vary during various periods.

15

Local currency sales growth was 17% for services during the third quarter of 2003 as compared with the third quarter of 2002. The continued increase in service revenue is associated with the installed base of laboratory water purification systems as well as increased validation support services for our customers in the other bioscience and biotechnology markets.

Gross Profit Margins

Gross profit margin percentages were 54.2% in the third quarter of 2003 as compared with 56.3% in the third quarter of 2002. The impact of foreign currencies reduced gross profit margins by approximately 50 basis points during the third quarter of 2003 and increased gross profit margins by approximately 10 basis points during the third quarter of 2002. The reduction in our gross profit margin percentage for the third quarter of 2003 as compared with the third quarter of 2002 was mainly due to additional overhead costs and depreciation for our recently expanded and upgraded manufacturing plants and unfavorable exchange rates which resulted in increased costs of our products manufactured in Europe. The manufacturing plants were expanded during the second half of 2002 to support increased levels of production in future periods.

Operating Expenses

Selling, general and administrative (“SG&A”) expenses increased $5,804, or 10.7%, in the third quarter of 2003 as compared with the third quarter of 2002. As a percentage of sales, SG&A expenses decreased from 30.9% to 30.0% from the third quarter of 2002 to the third quarter of 2003. In local currencies, SG&A increased at a rate of 5.9% in the third quarter of 2003 as compared with the third quarter of 2002. This increase was mainly due to increases in outside services, employee related costs and facilities costs which were partially offset by a decrease in travel and promotion programs.

Research and development (“R&D”) expenses increased $1,090, or 8.4%, in the third quarter of 2003 as compared with the third quarter of 2002. As a percentage of sales, R&D expenses decreased from 7.4% to 7.0% from the third quarter of 2002 to the third quarter of 2003. In local currencies, R&D remained constant in the third quarter of 2003 as compared with the third quarter of 2002. We continue to fund our planned R&D programs, including those in the development of technology, applications and products for protein applications, drug discovery and biopharmaceutical manufacturing. We expect our R&D programs will focus on the development of consumable products and hardware systems to meet our customers’ present and future needs.

Restructuring and Other

During the quarter ended September 30, 2003, we received proceeds of $1,250 and realized a gain of $796 in connection with a sale of real estate.

During the quarter ended September 30, 2002, we recorded an additional charge of $525 resulting in a total charge of $1,025 during the nine months ended September 30, 2002 related to litigation that was settled during the quarter ended December 31, 2002.

Net Interest Expense

Net interest expense decreased $1,049 in the third quarter of 2003 as compared with the third quarter of 2002. The lower net interest expense was a result of a higher cash balance and lower outstanding debt. Our cash and cash equivalents balance has increased $62,154 since the end of the third quarter of 2002 which resulted in higher interest income.

Provision for Income Taxes

Our effective tax rate on net income for the third quarter of 2003 was 22.5% as compared with 22.0% during the third quarter of 2002. The effective annual tax rate for 2003 is higher than the 2002 tax rate, because a greater portion of our profits will be generated in higher tax jurisdictions.

16

Nine months ended September 30, 2003 Compared to the Nine months ended September 30, 2002

Net Sales

The following discussion of net sales summarizes sales growth by the geographies in which our products were sold, the markets in which our products were used and major product types.

Net Sales by Geography

Sales growth by geography, measured in U.S. dollars and local currencies, for the first nine months of 2003 as compared with the first nine months of 2002 is summarized in the table below.

Sales by geography in U.S. dollars	Net sales				Percentage sales growth
	2003		2002
Americas	$	247,504	$	235,094	5	%
Europe		231,975		187,937	23	%
Asia/Pacific		104,393		95,341	10	%
Consolidated U.S. dollar net sales	$	583,872	$	518,372	13	%

Sales by geography in local currencies	Net sales					Percentage sales growth
	2003		2002
Americas	$	247,745	$	235,589		5	%
Europe		212,022		200,914		6	%
Asia/Pacific		105,223		101,687		3	%
Consolidated in local currencies		564,990		538,190		5	%
Foreign exchange		18,882		(19,818	)
Consolidated U.S. dollar net sales	$	583,872	$	518,372		13	%

	Percentage of net sales in U.S. dollars				Percentage of net sales in local currencies
	2003		2002		2003		2002
Americas	42	%	46	%	44	%	44	%
Europe	40	%	36	%	37	%	37	%
Asia/Pacific	18	%	18	%	19	%	19	%
Total	100	%	100	%	100	%	100	%

Net sales for the first nine months of 2003, measured in U.S. dollars, increased 13% as compared with net sales during the first nine months of 2002. Local currency sales increased 5% in the first nine months of 2003 as compared with the first nine months of 2002. The primary currencies impacting the difference between U.S. dollar results and local currency results, during the first nine months of 2003 as compared with the first nine months of 2002, were the Euro and the Japanese Yen. The U.S. dollar was weaker than the Euro by almost 17% and by approximately 6% against the Japanese Yen. A weaker U.S. dollar will positively impact U.S. dollar sales growth.

Local currency sales in the Americas increased 5% in the first nine months of 2003 as compared with the first nine months of 2002. Most of this increase was due to increased sales of consumable products within the other bioscience market and an increase in hardware sales within the biotechnology market. The hardware sales increase is largely due to the lower than usual sales base of the third quarter of 2002 which resulted in the first nine months of 2002 having low hardware sales. During the first nine months of 2003, hardware sales in America

17

grew consistently throughout the period. Local currency sales in Latin America increased 16%, off of a small base, in the first nine months of 2003 as compared with the first nine months of 2002, due to an increase in sales to biotechnology customers.

Local currency sales increased 6% in Europe during the first nine months of 2003 as compared with the first nine months of 2002. During the first nine months of 2003, sales of our consumable products within the biotechnology market increased 18% and increased more moderately in the other bioscience and life science research markets. Partially offsetting these increases was a decline in sales of our hardware products to our European customers as a result of the continued weak capital markets and weak economic conditions in Europe.

Local currency sales in the Asia/Pacific region increased 3% in the first nine months of 2003 as compared with the first nine months of 2002. Sales of consumable products within the biotechnology market increased 7% and 6% in our other bioscience market. These increases were partially offset by a decline in sales of our hardware products to our Asia/Pacific customers within the biotechnology market. Sales of hardware products within the biotechnology market are not significant as the Asia/Pacific biotechnology market is in its embryonic stage, thus significant percentage changes may occur as a result of the timing of a few transactions within a given period.

Net Sales by Market

Net sales growth in local currency for the first nine months of 2003 as compared with the first nine months of 2002, by market, is summarized in the table below.

Sales by market in local currencies	Net sales					Percentage sales growth
	2003		2002
Biotechnology	$	192,940	$	181,866		6	%
Life Science Research		79,182		76,495		4	%
Other Bioscience		292,868		279,829		5	%
Total local currency net sales by market		564,990		538,190		5	%
Foreign exchange		18,882		(19,818	)
Total U.S. dollar net sales by market	$	583,872	$	518,372		13	%

	Percentage of net sales in local currency
	2003		2002
Biotechnology	34	%	34	%
Life Science Research	14	%	14	%
Other Bioscience	52	%	52	%
Total	100	%	100	%

Local currency sales grew 6% in the biotechnology market during the first nine months of 2003 as compared with the first nine months of 2002. Sales within the biotechnology market of consumables increased almost 8%, but were partially offset by a 2% decline in sales of hardware products. The increase in consumable sales was partially a result of a $7,250 shipment of a chromatography media order in Europe as well as an increase in customer orders for our consumable products across all regions.

Local currency sales grew 4% in the life science research market during the first nine months of 2003 as compared with the first nine months of 2002. This increase was due to sales of consumable products associated with our laboratory water purification systems and sales of products related to protein applications. During 2003, sales in the life science research market increased in Europe and Asia/Pacific and to a lesser degree in the Americas. The increase in consumable sales within the life science research market was across all geographies.

18

Local currency sales growth of 5% in the other bioscience market during the first nine months of 2003 as compared with the first nine months of 2002 was primarily due to increased sales of consumable products and services across all geographies.

Net Sales by Major Product Type

Net sales growth (decline) by product type, measured in local currencies for the first nine months of 2003 as compared with the first nine months of 2002, is summarized in the table below.

Sales by product type in local currencies	Net sales					Percentage sales growth (decline)
	2003		2002
Consumables	$	443,819	$	417,528		6	%
Hardware		101,017		103,449		(2	)%
Services		20,154		17,213		17	%
Total local currency net sales by product		564,990		538,190		5	%
Foreign exchange		18,882		(19,818	)
Total U.S. dollar net sales by product	$	583,872	$	518,372		13	%

	Percentage of net sales in local currency
	2003		2002
Consumables	79	%	78	%
Hardware	18	%	19	%
Services	3	%	3	%
Total	100	%	100	%

Local currency sales growth of 6% in consumables during the first nine months of 2003 as compared with the first nine months of 2002 is due to the timing of customer needs. Customers’ ordering patterns are based on their therapeutic production volumes, timing of drug approvals and their commercial success as well as process yields and deployment of new process developments. Sales of consumables grew by 10% in Europe and by lesser amounts in the Americas and Asia/Pacific.

Local currency sales decreased 2% in hardware during the first nine months of 2003 as compared with the first nine months of 2002. Throughout 2003 a number of hardware projects have been delayed by our customers in the biotechnology market as funding of new research and development programs and many capital expansion programs have been constrained. During the third quarter of 2003, we began shipping product related to some of those previously delayed projects, but we do not have any assurances that we will record sales related to projects that have continued to be deferred.

Local currency sales growth was 17% for services during the first nine months of 2003 as compared with the first nine months of 2002. The continued increase in service revenue across all markets is due to service revenues associated with the installed base of water filtration systems as well as increased validation support services to our biotechnology and non-biotechnology pharmaceutical customers.

Gross Profit Margins

Gross profit margin percentages were 55.1% in the first nine months of 2003 as compared with 57.4% in the first nine months of 2002. The impact of foreign currencies reduced gross profit margins by approximately 10 basis points in the first nine months of 2003 and increased gross profit margins by approximately 50 basis points in the first nine months of 2002. The reduction in our gross profit margin percentage for the first nine months of

19

2003 as compared with the first nine months of 2002 was mainly due to additional costs and depreciation expense for our recently expanded manufacturing plants and unfavorable exchange rates. The manufacturing plants were expanded during the second half of 2002 to support increased levels of production in future periods.

Operating Expenses

SG&A expenses increased $18,799, or 11.5%, in the first nine months of 2003 as compared with the first nine months of 2002. As a percentage of sales, SG&A expenses decreased from approximately 31.5% to 31.1% from the first nine months of 2002 to the first nine months of 2003. In local currencies, SG&A increased at a rate of 4.6% in the first nine months of 2003 as compared with the first nine months of 2002. This increase was mainly due to increases in employee related costs, facilities and outside services, which were partially offset by lower travel expenses and fewer promotion programs during the first nine months of 2003.

R&D expenses increased $3,050, or 7.8%, in the first nine months of 2003 as compared with the first nine months of 2002. As a percentage of sales, R&D expenses decreased from 7.5% to 7.2% from the first nine months of 2002 to the first nine months of 2003. In local currencies, R&D increased at a rate of 4.2% in the first nine months of 2003 as compared with the first nine months of 2002. We continued to fund our planned R&D programs, including those in the development of technology, applications and products for protein applications, drug discovery and biopharmaceutical manufacturing.

Restructuring and Other

During the first nine months of 2003, we received proceeds of $1,250 and realized a gain of $796 in connection with a sale of real estate. We also completed the restructuring program that we had initiated during 2001 and recovered approximately $250 in assets that we had originally written-off and deemed uncollectible. Upon completion of this restructuring program we reversed $604 of the original estimated reserve, which included the $250 recovered during 2003 and $354 of previously estimated lease and severance payments, as these amounts were no longer required. During the first nine months of 2002, we recorded charges of $1,025 related to litigation that became estimable during that period and was settled during the year ended December 31, 2002.

Net Interest Expense

Net interest expense decreased $3,047 in the first nine months of 2003 as compared with the first nine months of 2002. The lower net interest expense was a result of a higher average cash balance, lower average interest borrowing rates and lower outstanding debt. At the end of the first quarter of 2002, we refinanced our 7.2% $100,000 public debt with available borrowing capacity under a revolving credit agreement which had a lower variable interest rate that is based on LIBOR.

Provision for Income Taxes

Our effective tax rate on net income for the first nine months of 2003 was 22.5% as compared with 22.0% during the first nine months of 2002. The effective annual tax rate for 2003 is higher than the 2002 tax rate, because a greater portion of our profits will be generated in higher tax jurisdictions.

Discontinued Operations

On October 3, 2000, we announced our plans, subject to certain conditions, to separate into two distinct companies by making our Microelectronics business segment an independent, publicly traded company. In accordance with these plans, the Microelectronics business segment was separated into a wholly owned Millipore subsidiary named Mykrolis Corporation (“Mykrolis”) on March 31, 2001. On August 9, 2001, Mykrolis

20

completed an initial public offering (the “Mykrolis IPO”) of 7,000 Mykrolis common shares at a price of $15.00 per share. Prior to the Mykrolis IPO, our ownership in Mykrolis’ outstanding common shares was 100%, and at December 31, 2001 our ownership in Mykrolis’ outstanding common shares was approximately 82%. On February 27, 2002 (the “Distribution Date”), we distributed our remaining ownership interest in Mykrolis common stock as a dividend to our shareholders of record as of February 13, 2002. During the first quarter of 2002, the amount of loss from discontinued operations that we had estimated during the year ended December 31, 2001 was reduced by $2,900 to reflect the actual net loss of Mykrolis through the Distribution Date.

Market Risk

We are exposed to market risks, which include changes in foreign currency exchange rates as measured both against the U.S. dollar and each other. We manage these market risks through our normal financing and operating activities and, when appropriate, through the use of derivative financial instruments.

We are exposed to foreign currency exchange rate risk inherent in sales, net income and assets and liabilities denominated in currencies other than the U.S. dollar. The potential change in foreign currency exchange rates offers a substantial risk to us, as on average approximately 55% of our business is conducted outside of the United States, generally in foreign currencies. Our risk management strategy currently uses forward contracts to mitigate certain foreign currency exposures. The intent is to offset gains and losses that occur on the underlying exposures, with gains and losses resulting from the forward contracts. These contracts principally relate to the Euro, Japanese Yen and British Pound. The periods of these forward contracts typically span less than three months. We held forward foreign exchange contracts with U.S. equivalent notional amounts totaling $64,137 at September 30, 2003. The fair value of these contracts was $22 at September 30, 2003. We do not enter into derivatives for trading or other speculative purposes, nor do we use leveraged financial instruments.

Although we attempt to manage our foreign currency exchange risk through the above activities, when the U.S. dollar strengthens against other currencies in which we transact business, sales and net income will be adversely impacted.

Capital Resources and Liquidity

Cash flow provided from operations was $88,221 in the first nine months of 2003 as compared with $69,067 in the first nine months of 2002. The increase in cash flow from operations in the first nine months of 2003 compared with the first nine months of 2002 was primarily the result of increased net income, increased accrued expenses and accrued income taxes partially offset by increases in inventory and accounts receivable balances.

Accounts receivable increased $8,701 at September 30, 2003 as compared with December 31, 2002. The increase in accounts receivable resulted in an increase in days sales outstanding in U.S. dollars of 2 days, from 79 days at December 31, 2002 to 81 days at September 30, 2003. Accounts receivable balances increased slightly in Europe and the Americas while remaining consistent in the Asia/Pacific region. The overall increase was primarily the result of increased sales volumes in the latter portion of the quarter ended September 30, 2003.

Inventory increased $14,759 at September 30, 2003 as compared with December 31, 2002. Approximately $9,100 of the increase in inventory was the result of purchases for key raw materials and in anticipation of fourth quarter sales. At September 30, 2003, approximately $2,500 of the increase in inventory related to the purchases of key raw materials is not expected to be used within the next 12 months.

During the first nine months of 2003, the change in accrued income taxes benefited our cash position by $5,737 due to lower payments being required. During the first nine months of 2002, we used $2,385 of cash to remit additional estimated tax payments and tax settlements in Europe and the U.S.

21

A portion of the operating cash flow during the first nine months of 2003 was used in investing activities for the purchase of property, plant and equipment. We purchased $49,326 of property, plant and equipment during the first nine months of 2003 as compared with $48,121 during the first nine months of 2002. We expect to purchase an additional $25,000 to $30,000 during the remainder of 2003. Our 2003 additions are being driven principally by our continued need to upgrade and add manufacturing capacity in the U.S. and Europe.

During the first nine months of 2003, we invested an additional $445, for a cumulative total of $7,908 invested to date, related to a planned $30,000 project to expand manufacturing capacity adjacent to our existing manufacturing facility in Ireland. We have delayed completion of this facility as existing manufacturing capacity related to a core consumable product line supplemented with the stockpiling initiative can meet the expected demand of this product line through 2006. We do not expect to complete construction of this facility prior to 2006. This facility is currently a multipurpose building shell that is expected to increase manufacturing capacity for this product line. If necessary, this facility could be used for the manufacturing of alternative products.

During the first nine months of 2002, we purchased substantially all of the net assets of CPG, Inc. for $11,676. Also during the first nine months of 2002, we made an investment and purchased intangible assets for $2,609 from our cash flows from investing activities.

Cash flows from financing activities during the first nine months of 2003 were principally a result of receiving $10,611 from employees exercising stock options and purchasing shares of our common stock in accordance with our Employees’ Stock Purchase Plan (“ESPP”). During the first nine months of 2002, we received $13,749 from employees exercising stock options and purchasing shares of our common stock in accordance with our ESPP and we paid $5,266 in dividends that had been declared for the fourth quarter of 2001. Beginning in 2002, we discontinued dividend payments.

During the first nine months of 2002, we funded Mykrolis $3,452 to support Mykrolis’ operations, prior to the Distribution Date.

In 2001, we entered into a five year unsecured revolving credit agreement that allows for revolving loan borrowings of up to $250,000. As of September 30, 2003, we have drawn $155,000 against our credit agreement. The revolving credit agreement calls for us to maintain certain financial covenants in the areas of leverage and interest coverage. We are compliant with all required covenants. In addition, we have a $75,000 7.23% note that will become due in March 2004. It is our intention and we believe that we have the ability to obtain new debt at prevailing market rates or utilize available borrowing capacity under our revolving credit agreement to refinance the 7.23% note when it becomes due in March 2004.

We believe that our balances of cash and cash equivalents, funds available under the credit agreement and cash flows expected to be generated by future operating activities will be sufficient to meet our cash requirements over the next twelve to twenty-four months.

Legal Proceedings

We are currently not a party to any material legal proceeding and we do not know of any material legal proceeding contemplated by any governmental authority.

We are subject to a number of claims and legal proceedings which, in our opinion, are incidental to our normal business operations. In our opinion, although final settlement of these suits and claims may impact our consolidated financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on our consolidated financial position, results of operations and cash flows.

22

Forward-Looking Statements

The matters discussed in this Form 10-Q, as well as in future oral and written statements by our management, that are forward-looking statements are based on our current management expectations. These expectations involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. These risks and uncertainties include without limitation, foreign exchange rates; regulatory delay in the approval of new therapeutics and their ultimate commercial success; further consolidation of drug manufacturers; competitive factors such as new membrane technology; lack of availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general and in the bioscience markets in particular; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in our filings with the Securities and Exchange Commission.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.

The information called for by this item is set forth under the heading “Market Risk” in Management’s Discussion and Analysis contained in this Form 10-Q which information is hereby incorporated by reference.

Item 4.    Controls and Procedures.

An evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the fiscal quarter covered by this report. Based upon that evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported in accordance with and within the time periods specified in Securities and Exchange Commission rules and forms.

PART II

Item 6.    Exhibits and Reports on Form 8-K.

a. Exhibits.

31.1 Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (17 CFR 240.13a-14(a)) or Rule 15d-14(a) (17 CFR 240.15d-14(a))

31.2 Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (17 CFR 240.13a-14(a)) or Rule 15d-14(a) (17 CFR 240.15d-14(a))

32.1 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

b. Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission:

On July 16, 2003, we furnished a Form 8-K that included a copy of the July 16, 2003 press release related to our financial results for the quarter ended June 30, 2003.

23

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Signature	Title	Date
/s/    KATHLEEN B. ALLEN         Kathleen B. Allen	Vice President and Chief Financial Officer	November 7, 2003
/s/    DONALD B. MELSON         Donald B. Melson	Corporate Controller (Chief Accounting Officer)	November 7, 2003

24

Exhibit Index

Exhibit Number	Exhibit Title
31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) (17 CFR 240.13a-14(a)) or Rule 15d-14(a) (17 CFR 240.15d-14(a))
31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (17 CFR 240.13a-14(a)) or Rule 15d-14(a) (17 CFR 240.15d-14(a))
32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

25